ArticleMedicine2026
Impact of lymph node dissection on survival outcomes in gastric cancer patients receiving immune checkpoint inhibitors.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of lymph node dissection in gastric cancer (GC) patients undergoing immune checkpoint inhibitor (ICI) therapy remains unclear. While extensive lymph node dissection has been a cornerstone of GC surgery, its impact on the efficacy of ICIs, which rely on immune functionality, warrants investigation. This retrospective study analyzed 218 GC patients treated with ICIs and compared their outcomes based on the number of lymph nodes dissected. Propensity score matching and multivariate Cox regression analyses were conducted to minimize confounding factors and identify independent prognostic variables. Subgroup analyses were performed based on lymph node metastasis status to explore potential interactions. Patients with fewer lymph node dissections demonstrated significantly longer progression-free survival (χ2 = 4.714, P = .030) and overall survival (χ2 = 5.826, P = .009) compared to those with extensive dissections. Subgroup analyses revealed that this association persisted in patients with positive lymph node metastasis but was less evident in those without metastasis, likely due to group imbalance. Propensity score matching analysis further supported the association between fewer lymph node dissections and improved survival outcomes. However, multivariate analysis indicated that the number of lymph nodes dissected was not an independent prognostic factor. This study revealed that a lower number of lymph node dissections is associated with improved recurrence-free survival and overall survival in GC patients receiving ICIs, suggesting a potential benefit of preserving immune-active lymph nodes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.